A large USA-based venture capital firm is currently investing from its eighth fund, which raised $400 million in 2014. The firm is open to investment opportunities globally.
The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices and diagnostics, and has a lesser interest in technology-led companies in the healthcare IT space (not interested in service-based/SaaS healthcare IT businesses). The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies. Due to the firm’s emphasis on new platforms, the firm generally does not invest in single asset companies.
While the firm invests across many areas, one focus at present is immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on immune priming or changing the immune system. Any immunological therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.
The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com





Leave a comment